Rheumatology International

, Volume 23, Issue 5, pp 231–235

The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis

Original Article



The intent of this study was to assess the effect of low-dose methotrexate treatment on bone mineral density (BMD) in patients with early rheumatoid arthritis (RA).


Forty-six premenopausal women with early RA not previously treated with disease-modifying antirheumatic drugs or corticosteroid were randomized to 7.5 mg/week of methotrexate or 2 g/day of sulphasalazine for 18 months. Bone mineral density of the lumbar spine, femoral neck, and trochanter was measured using dual-energy X-ray absorptiometry (DEXA). Biochemical studies included serum calcium, phosphorus, total alkaline phosphatase, beta-2 microglobulin, parathyroid hormone and 25-hydroxyvitamin D3 concentrations, spot urinary calcium, and 24-h urinary calcium excretion. Disease activity was assessed by modified disease activity score (DAS 28), and functional impairment was estimated by the Health Assessment Questionnaire.


No significant difference in BMD of the lumbar spine, femur neck, or trochanter was observed at 18 months in either group. There was also no significant change in the biochemical parameters of both groups.


Our findings suggest that low-dose methotrexate has no negative effect on BMD in premenopausal RA patients.


Methotrexate Osteoporosis Rheumatoid arthritis Sulphasalazine 


  1. 1.
    Van Jaarsveld CH, Jacobs JWG, Van Der Veen MJ, Blaauw AAM, Kruize AA, Hofman DM, Brus HLM (2000) Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 59:468–477CrossRefPubMedGoogle Scholar
  2. 2.
    Wolfe F (1990) Fifty years of antirheumatic therapy: the prognosis of rheumatoid arthritis. J Rheumatol 17:24–35PubMedGoogle Scholar
  3. 3.
    Prevoo MLL, Van Gestel AM, Van t'Hof MA, Van Rijswýjk MH, Van De Putte LBA, Van Riel PLCM (1996) Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 35:1101–1105CrossRefPubMedGoogle Scholar
  4. 4.
    Gough AKS, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27PubMedGoogle Scholar
  5. 5.
    Dequeker J, Maenaut K, Verwilghen J, Westhowens R (1995) Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 13 [Suppl 12]:S1–S6Google Scholar
  6. 6.
    Suzuki Y, Mizushima Y (1997) Osteoporosis in rheumatoid arthritis. Osteoporos Int 7 [Suppl 3]:S217–S222Google Scholar
  7. 7.
    Celiker R, Gokce-Kutsal Y, Cindas A, Ariyurek M, Renda N, Koray Z, Basgoze O (1995) Osteoporosis in rheumatoid arthritis: effect of disease activity. Clin Rheumatol 14:429–433PubMedGoogle Scholar
  8. 8.
    Laan RFJM, van Riel PLCM, van de Putte LBA (1992) Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis 51:826–832PubMedGoogle Scholar
  9. 9.
    Haugeberg G, Uhlig T, Flach JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Results from 394 patients in the Oslo country rheumatoid arthritis register. Arthritis Rheum 43:522–530CrossRefPubMedGoogle Scholar
  10. 10.
    Kroger H, Honkanen R, Saarikoski S, Alhave E (1994) Decreased axial BMD in perimenopausal women with rheumatoid arthritis—a population-based study. Ann Rheum Dis 53:18–23PubMedGoogle Scholar
  11. 11.
    Iwamoto J, Takeda T, Ichimura S (2002) Forearm bone mineral density in postmenopausal women with rheumatoid arthritis. Calcif Tissue Int 70:1–8CrossRefPubMedGoogle Scholar
  12. 12.
    Cortet B, Guyot MH, Solau E, Pigny P, Dumoulin F, Flipo RM (2000) Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol 18:683–690PubMedGoogle Scholar
  13. 13.
    Eastgate JA, Wood NC, Di Giovine FS, Symons JA, Grinlinton FM, Duff GW (1988) Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 340:706–709Google Scholar
  14. 14.
    Deodhar AA, Woolf AD (1996) Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 35:309–322PubMedGoogle Scholar
  15. 15.
    Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1995) Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 22:1055–1059PubMedGoogle Scholar
  16. 16.
    Saario R, Sonninen P, Mottonen T, Viikari J, Toivanen A (1999) Bone mineral density of the lumbar spine in patients with advanced rheumatoid arthritis: influence of functional capacity and corticosteroid use. Scand J Rheumatol 28:363–367CrossRefPubMedGoogle Scholar
  17. 17.
    Weinblatt ME, Majer AL, Fraser PA, Coblyn JJ (1998) Long-term prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 25:238–242PubMedGoogle Scholar
  18. 18.
    Ferraccioli GF, Bartoli E (1998) Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis. Clin Exp Rheumatol 16:662–666PubMedGoogle Scholar
  19. 19.
    Kerstens PJ, Boerbooms AM, Jeurissen MEC, de Graaf R, Mulder J, van de Putte LB (2000) Radiological and clinical results of long-term treatment of rheumatoid arthritis with methotrexate and azathoprine. J Rheumatol 27:1148–1155PubMedGoogle Scholar
  20. 20.
    Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC (1994) Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 37:1492–1498PubMedGoogle Scholar
  21. 21.
    Schwarts AM, Leonidas JC (1984) Methotrexate osteopathy. Skeletal Radiol 11:13–16PubMedGoogle Scholar
  22. 22.
    Stevens H, Jacobs JWG, Van Rijk P, De Klerk JMH (2001) Methotrexate osteopathy demonstrated by Technetium-99m HDP scintigraphy. Clin Nuc Med 5:389–391CrossRefGoogle Scholar
  23. 23.
    Maenpaa HM, Soini I, Lehto MUK, Belt EA (2002) Insufficiency fractures in patients with chronic inflammatory joint disease. Clin Exp Rheumatol 20:77–79PubMedGoogle Scholar
  24. 24.
    Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ (1996) Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 132:184–187PubMedGoogle Scholar
  25. 25.
    May KP, Mercill D, Mcdermott MT, West SG (1996) The effect of methorexate on mouse bone cells in culture. Arthritis Rheum 39:489–494PubMedGoogle Scholar
  26. 26.
    Van Der Veen MC, Scheven BAA, Van Roy JLAM, Damen CA, Lafeber FPJG, Bulsma JWJ (1996) In vitro effects of methotrexate on human articular cartilage and bone-derived osteoblasts. Br J Rheumatol 35:342–349PubMedGoogle Scholar
  27. 27.
    Blum M, Wallenstein CJ, Luckey M (1996) Effect of methotrexate on bone in postmenopausal women with primary biliary cirrhosis. J Bone Miner Res 11:T545Google Scholar
  28. 28.
    Cranney AB, McKendry RJ, Wells GA, Daylily SOOI, Kanisberg ND, Kraag GR, Smith D (2001) The effect of low dose methotrexate on bone density. J Rheumatol 28:2395–2399PubMedGoogle Scholar
  29. 29.
    Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1997) Effects of low dose methotrexate on bone mineral density of patients with rheumatoid arthritis. J Rheumatol 29 1489–1494Google Scholar
  30. 30.
    Mazzantini M, Di Munno O, Incerti-Vecchi L, Pasero G (2000) Vertebral bone mineral density changes in female rheumatoid arthritis patients treated with low-dose methotrexate. Clin Exp Rheumatol 18:327–331PubMedGoogle Scholar
  31. 31.
    Arnett FC, Edworthy SM, Bloch DA, et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedGoogle Scholar
  32. 32.
    Prevoo MLL, Van t'Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedGoogle Scholar
  33. 33.
    Kirwan JR, Reeback JS (1986) Stanford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 25:206–209PubMedGoogle Scholar
  34. 34.
    Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF (1993) Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 20:639–644Google Scholar
  35. 35.
    Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF (2000) Long-term methotrexate use in rheumatoid arthritis: 12 year follow-up of 460 patients treated in community practice. J Rheum 27:1864–1871PubMedGoogle Scholar
  36. 36.
    Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, Frediani B, Cantatore F, Pellerito R, Bartolone S, La Montagna G, Adami S (2000) A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on bone mass in rheumatoid arthritis. J Rheumatol 27:2582–2589PubMedGoogle Scholar
  37. 37.
    Preston SJ, Clifton-Bligh P, Laurent MR, Jackson C, Mason RS(1997) Effect of methotrexate and sulphasalazine on UMR 106 rat osteosarcoma cells. Br J Rheumatol 36:178–184CrossRefPubMedGoogle Scholar
  38. 38.
    Cantatore FP, Acquista CA, Pipitone V (1999) Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 26:2318–2323PubMedGoogle Scholar
  39. 39.
    Rico H, Ripoll E, Revilla M, Relea P, Villa LF(1993) β2-microglobulin in postmenopausal osteoporosis. Calcif Tissue Int 53:78–80PubMedGoogle Scholar
  40. 40.
    Moe SM, Sprague SM (1992) Beta2-microglobulin induces calcium efflux from cultured neonatal mouse calvaria. Am J Physiol 263:540–545Google Scholar
  41. 41.
    Shenstone BD, Mahmoud A, Woodward R, Elvins D, Palmer R, Ring EF, Bhalla AK (1994) Longitudinal bone mineral density changes in early rheumatoid arthritis. Br J Rheumatol 33:541–545PubMedGoogle Scholar
  42. 42.
    Keller C, Hafström I, Svensson B (2001) Bone mineral density in women and men with early rheumatoid arthritis. Scand J Rheumatol 30:213–220CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Department of Physical Therapy and RehabilitationOsmangazi University Medical SchoolEskisehirTurkey

Personalised recommendations